Allergan Aesthetics announces Health Canada Authorization for HArmonyCa® with Lidocaine, a next generation collagen stimulation injectable, that combines hyaluronic acid (HA) and calcium hydroxyapatite (CaHA) in one injection.
Through the patented DART® technology, HArmonyCa provides an instant lift, and drives collagen renewal.
HArmonyCa® is intended for facial soft tissue augmentation via injection into deep dermal and sub-dermal layers. It is a ready-to-use, dual effect injectable. The hyaluronic acid particles work deep within the skin, where they help plump it for a lifting effect, while the CaHA microspheres work to support the body’s own collagen production so new collagen fibres start to grow.1 Patients can see a lifted look immediately, while collagen production results in natural-looking results that last up to 18 months.
“As we age, loss of collagen can impact skin elasticity and structure,” says Dr. Nathan Rosen, Dermatologist with Dermetics Cosmetic Dermatology. “The availability of a dual-action injectable in Canada, that combines the lifting benefits of hyaluronic acid with collagen-stimulating calcium hydroxyapatite offers an exciting new approach for patients seeking natural-looking results, and for practitioners looking to address multiple aesthetic concerns with a single treatment.”
Loss of facial volume and changes to the soft-tissue are two of the most common signs of aging.6,7,8 In global research exploring people’s attitudes to aging and aesthetics, almost all respondents (96%, N=12,360) had a concern about an area of their face, with more than a third stating they were concerned about the quality of their skin (40%, N=12,360) or its loss of tightness (39%, N=12,360).
When asked if they would consider a non-surgical aesthetic treatment that stimulates their body to increase its production of collagen in the skin, two-thirds of people said they would (67%, N=12,360).
“HArmonyCa® represents our continued commitment to bringing the latest innovations to practitioners, and meaningful treatments with the best possible outcomes for patients, says Robert Schuller, General Manager, Allergan Aesthetics Canada. “This next generation injectable is designed to address some of the common signs of ageing with both immediate and longer-term benefits”.
Significant clinical improvements have been demonstrated with HArmonyCA® with Lidocaine from baseline to subsequent follow up in a clinical study (N=162), with: 91.6% of patients registering an improvement in general appearance of facial areas treated with HArmonyCa®.
In a late follow-up satisfaction cohort (N=45). 1 out of 5 patients reported a high overall satisfaction and a likeliness to repeat a similar treatment up to 19 months after receiving HArmonyCa®.
HArmonyCa® has been clinically shown to deliver a low risk to benefit profile.10 In a post marketing clinical analysis of HArmonyCa® (N=162), commonly occurring side effects (erythema, swelling, pain, tenderness and itching) were manageable and self- limiting.
A full list of side-effects, contraindications, warnings and precautions can be found in the HArmonyCa® Directions for Use.
